Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication
Study Details
Study Description
Brief Summary
Acute ethanol intoxication is the most frequent pathologic condition developing in subjects using alcohol. The severity of disorders in acute alcohol intoxication is determined, first of all, by the quantity of consumed alcohol and the duration of the toxic effect. When toxic doses of alcohol are taken per os, a life-threatening condition develops, which is manifested by consciousness depression and severe metabolism disorders. Reamberin (1.5 % meglumine sodium succinate solution) is an infusion solution with a balanced electrolyte composition and succinic acid, which is recommended for rehydration and detoxication in patients with intoxications of different genesis. The metabolic effect of Reamberin helps restore homeostasis and improve the natural organism detoxication. The investigators suppose that administration of Reamberin to patients with acute ethanol intoxication will make it possible to improve the treatment quality as compared to the standard therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
All drugs will be administered according to the instruction for medical use and conventional clinical practice.
The decision on the selection of therapy shall be made by a medical investigator irrespective of the protocol before the inclusion of a patient in the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| The control group Standard therapy |
|
| The test group Standard therapy + Reamberin |
Drug: Reamberin
Reamberin® in the average daily dose of 10 ml/kg daily
|
Outcome Measures
Primary Outcome Measures
- Difference in the average stay duration at ICU between patient groups. [Up to 2 weeks]
- Difference in the average consciousness recovery duration between patient groups. [Up to 2 weeks]
Secondary Outcome Measures
- Difference in average blood lactate levels between the groups, measured at the baseline and after 24 hours of the therapy [Baseline, 24 hours after the intervention]
- Difference in average serum bicarbonate levels between the groups, measured at the baseline and after 24 hours of the therapy [Baseline, 24 hours after the intervention]
- Percentage of patients, whose consciousness recovered to Glasgow Coma Score of up to 14 after 24 hours of the therapy, measured in both groups. [24 hours after the intervention]
The Glasgow Coma Scale: 15 points - clear consciousness. 14-13 points - moderate stunning. 12-11 points - deep stunning. 10-8 points - sopor. 7-6 points - moderate coma. 5-4 points - deep coma. 3 points - terminal coma, brain death.
- Dynamics of serum bicarbonate levels during the study (at the baseline, in 24 hours, by the end of the treatment in ICU), measured in both groups. [Baseline, 24 hours after the intervention, up to 2 weeks]
- Dynamics of organ failure score according to SOFA scale during the study, measured in both groups. [Baseline, 24 hours after the intervention, up to 2 weeks]
Sepsis-related Organ Failure scale: min 0 points, max 24 points. The higher the total score, the higher the degree of multiple organ failure
- Dynamics of consciousness level score according to Glasgow Coma Scale during the study, measured in both groups. [Baseline, 24 hours after the intervention, up to 2 weeks]
The Glasgow Coma Scale: 15 points - clear consciousness. 14-13 points - moderate stunning. 12-11 points - deep stunning. 10-8 points - sopor. 7-6 points - moderate coma. 5-4 points - deep coma. 3 points - terminal coma, brain death.
- Dynamics of the total score according to ICDSC scale (Intensive Care Delirium Screening Checklist) during the study, measured in both groups [Baseline, 24 hours after the intervention, up to 2 weeks]
Intensive Care Delirium Screening Checklist: ыcore ≥ 4 - delirium
- Percentage of patients, who developed delirium, measured in both groups [Up to 2 weeks]
- Percentage of patients, who developed hospital-acquired pneumonia, measured in both groups [Up to 2 weeks]
- Percentage of patients, who developed extrapulmonary complications, measured in both groups. [Up to 2 weeks]
- Percentage of lethal outcomes for the whole study period, measured in both groups. [Up to 2 weeks]
- Percentage of patients, for whom it became necessary to administer ALV, over the whole study period, measured in both groups. [Up to 2 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female patients aged from 22 to 65 years.
-
It is planned to administer one of the following treatment types to the patient, as part of the routine clinical practice:
-
Standard fluid administration + Reamberin®. It is planned to administer the drug Reamberin® in the average daily dose of 10 ml/kg daily for the whole period of treatment at ICU.
-
Standard fluid administration (without the use of the drug Reamberin®).
-
Primary diagnosis: toxic effect of ethanol.
-
Blood ethanol concentration: 1.5 ‰ (per mille) and more.
-
Consciousness depression (Glasgow Coma Score = 7-12)
-
Metabolic acidosis: Base excess of venous blood: from -12 to -3 mmol/l.
-
Availability of the written consent of the patient or his (her) legally authorized representative.
Exclusion Criteria:
-
Use of other drugs containing malate or succinate.
-
Consciousness depression with Glasgow Coma Score of lower than 7.
-
Intoxication with addictive substances and psychotropic drugs.
-
Shock.
-
Body weight of less than 50 kg or more than 120 kg.
-
Data on the presence of malignant neoplasms.
-
Decompensation of chronic pulmonary diseases with the development of respiratory failure of degree II-III as at the time of inclusion in the study.
-
Pregnancy, breast feeding.
-
Craniocerebral injury or polytrauma.
-
Acute cerebrovascular accident.
-
Infection-inflammatory disease of CNS (meningitis, encephalitis etc.) and other variants of CNS function disorder not associated with ethanol intoxication.
-
Respiratory impairment requiring ALV.
-
Contraindications mentioned in the approved instructions for the use of the drugs used in the study.
-
A disease or the use of drugs, which, in the physician's opinion, can influence safety, tolerance and efficiency of the study drugs.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Buyanov City Clinical Hospital | Moscow | Russian Federation | ||
| 2 | KORSAKOV Medical Center | Moscow | Russian Federation | ||
| 3 | Negovsky Research Institute of General Intensive Care Medicine | Moscow | Russian Federation | ||
| 4 | City Clinical Hospital No. 2 | Novosibirsk | Russian Federation | ||
| 5 | City Clinical Hospital of Emergency Medicine No. 1 | Omsk | Russian Federation | ||
| 6 | Regional Clinical Hospital, | Ryazan' | Russian Federation | ||
| 7 | Dzhanelidze St. Petersburg Research Institute of Emergency Medicine | Saint Petersburg | Russian Federation | ||
| 8 | City Mariinskaya Hospital | St. Petersburg | Russian Federation | ||
| 9 | Yaroslavl Regional Clinical Narcological Hospital | Yaroslavl | Russian Federation |
Sponsors and Collaborators
- POLYSAN Scientific & Technological Pharmaceutical Company
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Reamberin\2022\01